Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles
International Journal of Molecular Sciences · 07.03.2023 · 24 (6) · 5088
DOI: 10.3390/ijms24065088 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.03.2023. Verfasst von Andrew A Bieberich und 1 weiteren Autor:innen. Beteiligte Einrichtung: AsedaSciences Inc., 1281 Win Hentschel Boulevard, West Lafayette, IN 47906, USA. Hauptthemen laut MEDLINE: Drug Discovery, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiat…, Janssen, Merck KGaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-…, NIH Common Fund Illuminating the Druggable Genome (IDG) program.
Abstract (Originalsprache)
There have been more than 70 FDA-approved drugs to target the ATP binding site of kinases, mainly in the field of oncology. These compounds are usually developed to target specific kinases, but in practice, most of these drugs are multi-kinase inhibitors that leverage the conserved nature of the ATP pocket across multiple kinases to increase their clinical efficacy. To utilize kinase inhibitors in targeted therapy and outside of oncology, a narrower kinome profile and an understanding of the toxicity profile is imperative. This is essential when considering treating chronic diseases with kinase targets, including neurodegeneration and inflammation. This will require the exploration of inhibitor chemical space and an in-depth understanding of off-target interactions. We have developed an early pipeline toxicity screening platform that uses supervised machine learning (ML) to classify test compounds’ cell stress phenotypes relative to a training set of on-market and withdrawn drugs. Here, we apply it to better understand the toxophores of some literature kinase inhibitor scaffolds, looking specifically at a series of 4-anilinoquinoline and 4-anilinoquinazoline model libraries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AsedaSciences Inc., 1281 Win Hentschel Boulevard, West Lafayette, IN 47906, USA.
- School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland.
- Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
- Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
ORCID-Profile: Christopher R M Asquith
Förderung
- AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiat…
- Janssen, Merck KGaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-…
- NIH Common Fund Illuminating the Druggable Genome (IDG) program
- National Science Foundation
Zitieren
APA
Bieberich, A. A., & Asquith, C. R. M. (2023). Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles. International Journal of Molecular Sciences, 24(6), 5088. https://doi.org/10.3390/ijms24065088
Vancouver
Bieberich AA, Asquith CRM. Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles. International Journal of Molecular Sciences. 2023;24(6):5088. doi:10.3390/ijms24065088
BibTeX
@article{Bieberich2023,
author = {Bieberich, Andrew A and Asquith, Christopher R M},
title = {Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {6},
pages = {5088},
doi = {10.3390/ijms24065088}
}
EUVIMED